Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

For those whose tumors also demonstrate HER2 amplification (extra copies of the HER2 gene), this therapy may be less effective. In the SWOG S1613 clinical trial comparing this standard therapy to ...

HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer ...

The HER2 gene makes a protein called HER2 (human epidermal growth factor receptor 2). This protein is found on the surface of all breast cells and that helps them grow. If the HER2 gene ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Meet the Innovator of the Year for Men's Health honoree for Atlanta Business Chronicle's Health Care Champion Awards.

They're given to women who have a mutation in the BRCA gene and HER2-negative breast cancer. Capivasertib (Truqap). This drug blocks some types of the AKT protein. It can be used if the cancer ...

A FISH test uses specialized fluorescent dye and DNA to show changes in chromosomes and can also show levels of the HER2 gene. Treating triple-positive breast cancer may include using a ...

Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

The Company is currently organizing additional data in relation to the recently-completed treatment phase of its Phase 2b trial of OST-HER2 in the prevention of recurrence of lung metastatic ...